SEGAL LLOYD MITCHELL reported 1 transaction at AKTIS ONCOLOGY, INC.
Review the transaction codes below to understand the nature of each event.
Filed: 1/12/2026ACC: 0001193125-26-010575
-55.06K
Net shares
Net seller
$0.00
Total acquired
0
Open market trades
0B · 0S
3
Total transactions
19.63K acquired · 74.69K disposed
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+19.63K
Price / share
—
Trade value
—
% of position
New position
1/12/2026
0.00→19.63K
Total
Net shares
+19.63K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 1/12/2026 | C · Conversion | +19.63K | — | — | New position | 0.00 | 19.63K |
| Total | +19.63K | $0.00 | ||||||
Derivative Transactions2
Series A Redeemable Convertible Preferred Stock
Indirect
Converts to
Common Stock
13.14K shares
Shares
−50K
Strike price
Held after
0.00
Exercisable
—
1/12/2026
Series B Redeemable Convertible Preferred Stock
Indirect
Converts to
Common Stock
6.49K shares
Shares
−24.69K
Strike price
Held after
0.00
Exercisable
—
1/12/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A Redeemable Convertible Preferred Stock Indirect | Common Stock13.14K shares | 1/12/2026 | C · Conversion | −50K | — | 0.00 | |
| Series B Redeemable Convertible Preferred Stock Indirect | Common Stock6.49K shares | 1/12/2026 | C · Conversion | −24.69K | — | 0.00 |